Drug Trial Radar · NCT07110584
Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors
Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
235
Planned (sponsor's estimate)
Start
Oct 1, 2025
Primary completion
Jun 30, 2031
Study completion Jun 30, 2031
Sponsor
- Lead sponsor
- ModeX Therapeutics, An OPKO Health CompanyIndustry
- Sponsor type
- Industry
- First posted
- Aug 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2004 in patients with advanced tumors.
Conditions
- Advanced Tumors
Interventions
MDX2004Drug
MDX2004 intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- All Study Parts: Adverse Events (AEs)Time frame: Baseline until 90 days after the participant has the last dose of MDX2004
- Part A only - Maximum Tolerated Dose (MTD) or Recommended Phase 2 dose (RP2D)Time frame: 28 days
- Part B, C, and D: Objective response rate of MDX2004Time frame: From date of enrollment until the end of treatment, up to approximately 6 months
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Liverpool Hospital
Liverpool, New South Wales, Australia · Recruiting
Calvary Mater Newcastle
Waratah, New South Wales, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
Rambam Health Care Campus
Haifa, Israel · Recruiting
Hadassah University Hospital-Ein Kerem
Jerusalem, Israel · Recruiting
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.